Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Renal and Pulmonary Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPC6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TRPC6 Lentivirus Premade Particles (High titer >10^8 TU/ml) for stable cell line construction; full-length ORF sequence verified. | View TRPC6 Products |
| Wild-Type Antigen | TRPC6 Full-length Detergent Solubilized Protein or Membrane Extract (HEK293 expressed, native glycosylation, Endotoxin <1EU/ug, >95% purity). | View TRPC6 Products |
| Mutant Antigen | TRPC6 FSGS-associated mutant proteins (gain-of-function variants, sequence verified, >95% purity). | View TRPC6 Products |
| Benchmark Ab | Anti-TRPC6 Recombinant Control Antibody (sequence verified positive control for western blot / IHC / flow cytometry). | View TRPC6 Products |
| Validator | TRPC6 siRNA Set for knockdown verification to ensure assay specificity. | View TRPC6 Products |
| Selectivity Panel A | TRPC3 Protein (highly homologous subfamily member for off-target liability screening). | View TRPC3 Products |
| Selectivity Panel B | TRPC7 Protein (cation channel with similar pharmacology; cross-reactivity counter-screen). | View TRPC7 Products |
| Pathway Partner A | AT1R (Upstream GPCR partner in podocyte dysfunction and cardiac hypertrophy). | View AT1R Products |
| Pathway Partner B | NPHS2 (Podocin) (Key podocyte scaffolding protein; functional interaction partner in glomerular filtration barrier). | View NPHS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Ion Channel Conformation | Lentivirus Premade Particles enable stable cell line generation to preserve native membrane topology and pore function. |
| Subfamily Off-Target Toxicity (TRPC3/7) | Human/Mouse TRPC3 and TRPC7 ortholog proteins (>95% purity) available for cross-reactivity panels. |
| Disease Mutant Mechanism | FSGS-associated mutants (gain-of-function) available for precision medicine assays. |
| Lack of Reliable Antibodies / Assay Specificity | Recombinant positive control antibodies (sequence verified) and validated siRNA sets to confirm TRPC6-specific signal and eliminate false positives. |
Live TRPC6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPC6 therapeutics is highly focused on small molecule inhibitors for chronic kidney diseases, particularly Focal Segmental Glomerulosclerosis (FSGS) and diabetic nephropathy. As an essential calcium-permeable non-selective cation channel, TRPC6 overactivation drives podocyte damage. First-generation inhibitors have provided proof-of-concept, and the next wave of R&D is targeting extreme selectivity over TRPC3 and TRPC7 to avoid systemic cardiovascular side effects, alongside exploration in pulmonary arterial hypertension (PAH) and pulmonary fibrosis. Additionally, mutant-specific pharmacology and genetic therapy approaches are emerging for patients with gain-of-function mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Boehringer Ingelheim, Vertex Pharmaceuticals (Goldfinch Bio), Dimer Bioscience | FSGS, Diabetic Nephropathy | Selectivity Assay: Need TRPC3/TRPC7 counter-screen proteins/stable cell lines via Lentivirus. |
| Small Molecule Agonist | Academic Consortia | Wound Healing, Ischemia | Calcium Flux Assay: Need native conformation TRPC6 expression. |
| Monoclonal Antibody | Early Preclinical | Fibrotic Diseases | Binding Assays: Need high-titer Lentivirus for flow cytometry. |
| Genetic Therapy | Academic Consortiums | Genetic FSGS (Rare) | Mutant vs WT Validation: Need FSGS mutant proteins (e.g., gain-of-function variants). |
| Phenotypic Screen | Emerging Biotech | Podocytopathy | Stable Cell Line: Lentivirus for consistent calcium flux assays. |